Domo signs strategic collaboration agreement with AWS for AI solutions
Acurx Pharmaceuticals LLC (ACXP) stock has hit a 52-week low, dropping to $0.66, as the company faces a challenging market environment. With a market capitalization of just $11.15 million and a beta of -1.71, InvestingPro data shows the stock tends to move counter to broader market trends. This latest price level reflects a significant downturn from previous periods, with the stock experiencing a steep 1-year change of -77.59%. Investors are closely monitoring ACXP as it navigates through the volatility, with the hope for potential recovery or strategic moves that could bolster the stock’s performance in the upcoming quarters. Despite current challenges, analyst price targets range from $10 to $12, and the company maintains a healthy current ratio of 1.8. With earnings due in 9 days, InvestingPro subscribers can access 7 additional key insights and a comprehensive research report for deeper analysis.
In other recent news, Acurx Pharmaceuticals, Inc. has announced significant developments regarding its lead antibiotic candidate, ibezapolstat. The company is preparing to advance ibezapolstat into international Phase 3 clinical trials for the treatment of C. difficile Infection (CDI), following positive feedback from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These trials will compare ibezapolstat to the standard-of-care treatment, vancomycin, focusing on achieving clinical cure and reducing CDI recurrence. The Phase 2 clinical trials demonstrated a 96% clinical cure rate with ibezapolstat, which was well-tolerated with no serious adverse events.
Acurx has also been granted a patent by the Japanese Patent Office for its DNA Polymerase IIIC Inhibitors, crucial for its ACX-375C program targeting Gram-positive bacterial infections. This patent is part of Acurx’s strategy to build a global patent portfolio, complementing its existing patents in the United States and Israel. Executive Chairman Robert J. DeLuccia highlighted the patent’s role in advancing their AI-supported drug discovery platform. Additionally, Acurx’s ibezapolstat has been recognized by the FDA as a Qualified Infectious Disease Product and granted Fast-Track Designation.
The company’s efforts are supported by regulatory guidance from both the FDA and EMA, aligning Acurx for potential marketing authorization in Europe. The EMA’s Scientific Advice Procedure affirmed the readiness of Acurx’s data package for Phase 3 trials. These developments underscore Acurx’s commitment to advancing treatments for difficult-to-treat bacterial infections while maintaining a focus on the health of the gut microbiome.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.